Table 1.
Past and current BC clinical trials related to HER2, PARP, EGFR, aryl hydrocarbon receptor (AhR), inducible nitric oxide (iNOS), and Wnt.
| Intervention/Therapy | Target Cancer Subtype | Clinical Trial Phase | Type | Status | Trial ID Reference (Clinicaltrials.gov) |
|---|---|---|---|---|---|
| KU 0059436 (olaparib), a PARP inhibitor | BRCA1- or BRCA2-positive advanced BC | Phase II | Treatment | Active | NCT00494234 |
| Preoperative combination of letrozole, everolimus, and TRC105 | Postmenopausal hormone-receptor positive and Her2 BC | Phase I | Treatment | Active | NCT02520063 |
| CDK4/6-inhibitor or chemotherapy, in combination with endocrine therapy | Advanced BC | Phase II | Treatment | Recruiting | NCT03227328 |
| LGK974 in patients with malignancies dependent on Wnt ligands | TNBC | Phase I | Treatment | Recruiting | NCT01351103 |
| Anti-EGFR-immunoliposomes loaded with DOX | Advanced triple negative EGFR positive BC | Phase II | Treatment | Active | NCT02833766 |
| Comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy | PIK3CA mutated advanced BC | Phase II | Treatment | Active | NCT03386162 |
| Peritumoral adipose tissue sample analyzing the concentrations of 46 persistent organics pollutants | Breast tumor patients (benign, malignant with and without lymph node metastasis) | N/A | Other | Completed | NCT03788187 |
| Seviteronel in combination with chemotherapy | Androgen-receptor-positive metastatic TNBC | Phase I, Phase II | Treatments | Not yet recruiting | NCT04947189 |